A Randomized, Double-Blind, Multicenter Study Evaluating The Safety and Efficacy of BTDS in Subjects With Moderate to Severe Osteoarthritis Pain. Includes a 52-Week Extension Phase.
Phase of Trial: Phase III
Latest Information Update: 31 Aug 2012
At a glance
- Drugs Buprenorphine (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions; Registrational
- Sponsors Purdue Pharma
- 08 Jun 2010 New trial record.